Satsuma Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing innovative treatments for people living with migraine, today announced that two abstracts highlighting findings from...
Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes. Exploratory Efficacy Endpoints showed that STS101...
